Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and usually requires the administration of adjuvant chemotherapy after surgery but even with this treatment many patients still suffer from a relapse. The main objective of this study was to identify proteomics-based biomarkers that predict the response to standard adjuvant chemotherapy, so that patients at are not going to benefit from it can be offered therapeutic alternatives.

Methods

We analyzed the proteome of a retrospective series of formalin-fixed, paraffin-embedded TNBC tissue applying high-throughput label-free quantitative proteomics. We identified several protein signatures with predictive value, which were validated with quantitative targeted proteomics in an independent co

SUBMITTER: Gamez-Pozo A 

PROVIDER: S-EPMC5464546 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature